Alcon : JP Morgan Healthcare Conference Presentation (

JP Morgan Healthcare Conference David J. Endicott, CEO

January 11, 2023

Legal Disclaimers

Forward-looking statements

This document contains, and our officers and representatives may from time to time make, certain "forward-looking statements" within the meaning of the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "anticipate," "intend," "commitment," "look forward," "maintain," "plan," "goal," "seek," "target," "assume," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding our liquidity, revenue, gross margin, operating margin, effective tax rate, foreign currency exchange movements, earnings per share, our plans and decisions relating to various capital expenditures, capital allocation priorities and other discretionary items such as our transformation program, market growth assumptions, our sustainability and diversity plans, targets, goals and expectations, and generally, our expectations concerning our future performance.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties and risks that are difficult to predict such as: cybersecurity breaches or other disruptions of our information technology systems; compliance with data privacy, identity protection and information security laws; our ability to comply with the US Foreign Corrupt Practices Act of 1977 and other applicable anti-corruption laws, particularly given that we have entered into a three-year Deferred Prosecution Agreement with the US Department of Justice; the impact of a disruption in our global supply chain or important facilities; supply constraints and increases in the cost of energy; our ability to forecast sales demand and manage our inventory levels and the changing buying patterns of our customers; our ability to manage environmental, social and governance matters to the satisfaction of our many stakeholders, some of which may have competing interests; our success in completing and integrating strategic acquisitions; the success of our research and development efforts, including our ability to innovate to compete effectively; global and regional economic, financial, legal, tax, political and social change; our ability to comply with all laws to which we may be subject; pricing pressure from changes in third party payor coverage and reimbursement methodologies; our ability to properly educate and train healthcare providers on our products; our reliance on outsourcing key business functions; our ability to attract and retain qualified personnel; the impact of unauthorized importation of our products from countries with lower prices to countries with higher prices; the ability to obtain regulatory clearance and approval of our products as well as compliance with any post-approval obligations, including quality control of our manufacturing; our ability to protect our intellectual property; our ability to service our debt obligations; the need for additional financing through the issuance of debt or equity; the effects of litigation, including product liability lawsuits and governmental investigations; effect of product recalls or voluntary market withdrawals; the accuracy of our accounting estimates and assumptions, including pension and other post-employment benefit plan obligations and the carrying value of intangible assets; legislative, tax and regulatory reform; the impact of being listed on two stock exchanges; the ability to declare and pay dividends; the different rights afforded to

our shareholders as a Swiss corporation compared to a US corporation; and the effect of maintaining or losing our foreign private issuer statusJP MORGANunder U.S. securities lawsHEALTHCARE.CONFERENCE Additional factors are discussed in our filings with the United States Securities and Exchange Commission, including our Form 20-F. Should one or more of these uncertainties or risks materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated. Therefore, you should not rely on any of these forward-looking statements. Forward-lookingINVESTORstatements in thisPRESENTATIONdocument speak

only as of the date of its filing, and we assume no obligation to update forward-looking statements as a result of new information, future events or otherwise.

Intellectual property

01.11.2023

This report may contain references to our proprietary intellectual property. All product names appearing in italics or ALL CAPS are trademarks owned by or licensed to Alcon Inc. Product names identified by a "®" or a "™" are trademarks that are not owned by or licensed to Alcon or its subsidiaries and are the property of their respective owners.

Non-IFRS measures

Alcon uses certain non-IFRS metrics when measuring performance, including when measuring current period results against prior periods, including core results, percentage changes measured in constant currencies and free cash flow. Because of their non-standardized definitions, the non-IFRS measures (unlike IFRS measures) may not be comparable to the calculation of similar measures of other companies. These non-IFRS measures are presented solely to permit investors to more fully understand how Alcon management assesses underlying performance. These non-IFRS measures are not, and should not be viewed as, a substitute for IFRS measures.

2

Resilient markets

driven by favorable megatrends

Aging	Increasing	Increasing	JP MORGAN HEALTHCARE CONFERENCE
New	Increasing Sense
Population	Wealth	Myopia	Technologies INVESTORof WellnessPRESENTATION
By 2050, more than	The middle class	An estimated 50%	Improving patient	People are more
2 billion people will	will grow by ~	of the world will be	outcomes and	determined to stay
be over age 601	1.7 billion people in	myopic by 20503	increasing access	fit and healthy
	10-15 years2

1.	World Health Organization. Multisectoral action for a life course approach to healthy ageing: draft global strategy and plan of action on ageing and health. 69th World Health
	Assembly, Geneva, 2016 April 22 (A69/17).	3
2.	Hamel, K and Kharas, H. A global tipping point: Half of the world is now middle class or wealthier. Brookings. 27 September 2018.
3.	B. Holden, T. Fricke, et al. Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050. Ophthalmology, 2016.

Alcon's strategy

We focus on eye care

We create value by applying specialty market and technical knowledge to create products that improve sight

Specialty market expertise

• Customer knowledge
• Market assessment
• Market development
• Global commercialization

Specialty technology expertise

• Materials science
• Surface chemistry
• Fluidics and energy delivery
• Optical engineering

Disciplined capital management

• Smart infrastructure
• Efficient operating model
• Open source innovation

(internal/external)	4

We aspire to lead the world in eye care innovation

37

Surgical launches1 sinceince 20182018

23 $680M+

Vison Care	Core R&D
launches1	investment
since 2018	in 2021
ince 2018	2020 versus 2018

JP MORGAN HEALTHCARE CONFERENCE

1.4K

R&D associates in20202021

˜2.1K

Active patent families2

100+

Active projects

in development

1.	As of 6 December 2022.	5
2.	As of 14 December 2022. Includes owned and in-licensed patent rights.